Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

J Mol Diagn 2014 Nov 23;16(6):660-72. Epub 2014 Aug 23.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic alterations in patients is playing an increasingly important diagnostic and/or prognostic role for many cancer types. However, the landscape of genomic abnormalities is still unknown for less common cancers, and the influence of specific genotypes on clinical behavior is often still unclear. To address some of these deficiencies, we developed Profile, a prospective cohort study to obtain genomic information on all patients at a large tertiary care medical center for cancer-related care. We enrolled patients with any cancer diagnosis, and, for each patient (unselected for cancer site or type) we applied mass spectrometric genotyping (OncoMap) of 471 common recurrent mutations in 41 cancer-related genes. We report the results of the first 5000 patients, of which 26% exhibited potentially actionable somatic mutations. These observations indicate the utility of genotyping in advancing the field of precision oncology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2014.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210463PMC
November 2014
85 Reads

Publication Analysis

Top Keywords

genomic abnormalities
8
patients
5
cancer
5
care medical
4
medical center
4
tertiary care
4
large tertiary
4
genomic patients
4
patients large
4
diagnosis patient
4
center cancer-related
4
enrolled patients
4
patients cancer
4
care enrolled
4
cancer-related care
4
study genomic
4
cancer diagnosis
4
prospective cohort
4
influence specific
4
specific genotypes
4

Similar Publications